Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
15. November 2024 00:59 ET
|
Regeneron Pharmaceuticals, Inc.
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by...
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
24. Oktober 2024 08:00 ET
|
Regeneron Pharmaceuticals, Inc.
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end; if...
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights
18. Juli 2024 10:05 ET
|
Spherix Global Insights
EXTON, PA, July 18, 2024 (GLOBE NEWSWIRE) -- In February of this year, Takeda’s Eohilia (budesonide oral suspension) received FDA approval as the first and only oral therapy for eosinophilic...
Global Dermatological Therapeutics Market Analysis & Forecast 2024-2034 by Drug Class, Application and Region - Featuring Eli Lilly & Company, Amgen, Johnson & Johnson, and Aclaris Therapeutics Among Others
08. April 2024 10:42 ET
|
Research and Markets
Dublin, April 08, 2024 (GLOBE NEWSWIRE) -- The "Global Dermatological Therapeutics Market Analysis & Forecast 2024-2034: Market By Drug Class; By Application; and By Region" report has been...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
23. Februar 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
Priority Review granted based on positive results from two Phase 3 trials; if approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in...
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
16. Februar 2024 00:59 ET
|
Regeneron Pharmaceuticals, Inc.
Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for...
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
25. Januar 2024 14:29 ET
|
Regeneron Pharmaceuticals, Inc.
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for...
Global Dermatology Drugs Market 2024-2034: Growth Accelerated by Surging Skin Disease Prevalence, New Product Launches, Robust R&D, Clinical Studies, Therapeutic Drug Approvals, Collaborative Innovations
25. Januar 2024 06:39 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Global Dermatology Drugs Market Analysis & Forecast 2024-2034: By Application; By Route of Administration; By Distribution Channel; and By Region"...
DUPIXENT Drug Insights and Market Forecasts, 2032
01. Dezember 2023 06:23 ET
|
Research and Markets
Dublin, Dec. 01, 2023 (GLOBE NEWSWIRE) -- The "DUPIXENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.DUPIXENT's potential as a game-changer...
An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
15. August 2023 15:40 ET
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...